Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

NCT02970292 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

396

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Pimavanserin
DRUG: Placebo

Sponsor

ACADIA Pharmaceuticals Inc.